-
Oct 21, 2024 | 
ard.bmj.com | Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Sep 30, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |George Bertsias |Dimitrios T. Boumpas
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Sep 19, 2024 | 
ard.bmj.com | Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Lupus Erythematosus, Systemic Therapeutics Lupus Nephritis We thank Drs Roberts et al for their interest in the updated EULAR recommendations for the management of systemic lupus erythematosus (SLE), and for the important points they raise.1 Prompted by a phrase in the manuscript text, that race, as an ‘immutable’ characteristic, should be taken into account during the choice of therapy for an individual patient with SLE, they argue that racial differences in treatment responses or other...
-
Apr 5, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |George Bertsias |Dimitrios T. Boumpas
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Jan 1, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer
Handling editor David S PisetskyTwitter @cmukhtyar, @edvital, @chriswincup, @george_bertsias, @noneContributors AF and MK reviewed the literature and AF drafted the manuscript. GB and CBM supervised the methodology. All authors edited the manuscript. DTB supervised the project. Funding European League against Rheumatism (project number QoC015).
-
Jan 1, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer
Dear Editor,The 2023 update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) recommend hydroxychloroquine (HCQ) for all patients with SLE at a target dose of 5 mg/kg real body weight (RBW)/day but also suggest individualizing the regimen in accordance with the risk of flares or retinal toxicity.
-
Oct 12, 2023 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer
DiscussionFor these recommendations, we assembled a Task Force of world-leading experts in the field of SLE from four continents, to assure the widest possible representation and broad expertise. This is particularly important, because SLE across the world is very different in terms of presentation and severity.
-
Oct 12, 2023 | 
dx.doi.org | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette Hammer Andersen |Martin Aringer
DiscussionFor these recommendations, we assembled a Task Force of world-leading experts in the field of SLE from four continents, to assure the widest possible representation and broad expertise. This is particularly important, because SLE across the world is very different in terms of presentation and severity.
-
Jul 13, 2023 | 
ard.bmj.com | Antonis Fanouriakis |Nikolaos Tziolos |George Bertsias |Dimitrios T. Boumpas
http://orcid.org/0000-0003-2696-031XAntonis Fanouriakis1, Nikolaos Tziolos2, George Bertsias3,4, http://orcid.org/0000-0002-9812-4671Dimitrios T Boumpas2 1 Department of Rheumatology, Asklepieion General Hospital, Athens, Greece 2 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece 3 Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Greece 4 Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and...
-
May 11, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
http://orcid.org/0000-0002-8832-7475Myrto Kostopoulou1, http://orcid.org/0000-0003-2696-031XAntonis Fanouriakis1,2, George Bertsias3,4, http://orcid.org/0000-0002-9812-4671Dimitrios T Boumpas1,5 1 Rheumatology and Clinical Immunology, National and Kapodistrian University, Athens, Greece 2 First Department of Propaedeutic Internal Medicine, National and Kapodistrian University, Athens, Greece 3 Rheumatology, University of Crete School of Medicine, Iraklio, Greece 4 Laboratory of...
